Testosterone Cypionate Side Effects: What the Label and Trials Show

    Testosterone cypionate side effects with numbers: injection-site reactions, hematocrit and clots, blood pressure, TRAVERSE heart data, estrogen, fertility, mood, skin.

    Testosterone cypionate side effects fall into three groups that are worth keeping apart: the ones the FDA label lists for replacement doses, the ones it lists separately under abuse at higher doses, and the ones blood tests catch before a man feels anything.

    The label's own adverse-reaction list has no frequencies, because it was written from case reports rather than a modern trial table. This page adds the numbers from the Azmiro single-dose study (2025), the TRAVERSE cardiovascular trial (5,198 men) and the Xyosted blood-pressure study where they exist. Everything here applies to any testosterone ester; nothing is specific to the cypionate form except the injection-site reactions.

    Key takeaway
    The common, visible effects are acne, oily skin, injection-site soreness, fluid retention and mood or libido change; the ones that drive monitoring are a rising hematocrit, blood pressure, suppressed sperm production and, in older men, PSA. TRAVERSE found no excess of heart attack or stroke with testosterone versus placebo over 33 months, but more venous clots, atrial fibrillation and fractures.

    What the Label Lists

    Adverse reactions in the Depo-Testosterone label (September 2025)

    System
    Reactions listed

    Endocrine and urogenital

    Gynecomastia; excessive frequency and duration of erections; oligospermia at high doses

    Skin

    Hirsutism, male pattern baldness, seborrhea, acne

    Cardiovascular and vascular

    Myocardial infarction, stroke; venous thromboembolism

    Fluid and electrolytes

    Retention of sodium, chloride, water, potassium, calcium and phosphate

    Liver and gut

    Nausea, cholestatic jaundice, altered liver tests; rarely hepatic neoplasms and peliosis hepatis (mainly with oral 17-alpha-alkylated androgens)

    Blood

    Polycythemia; suppression of clotting factors; bleeding on anticoagulants

    Nervous system and mood

    Increased or decreased libido, headache, anxiety, depression, paresthesia

    Other

    Hypersensitivity; central serous chorioretinopathy (rare); inflammation and pain at the injection site

    The only frequency the labels give for a replacement dose comes from Azmiro's 31-day study of 27 men after one 200 mg injection:

    1. 1Injection-site erythema: 26%, all mild
    2. 2Injection-site reaction: 4%, all mild

    Everything else is "has occurred with some androgens."


    Hematocrit and Blood Clots

    Testosterone stimulates red-cell production, and a rising hematocrit is the most common laboratory reason a prescriber changes a dose.

    The rules in use:

    1. 1Endocrine Society: above 54%, stop until the value falls, then restart at a lower dose or longer interval
    2. 2Azmiro label: a second rise after a restart means stopping for good
    3. 3Injections produce higher peaks than gels and therefore higher hematocrits on average, one argument for weekly rather than biweekly dosing

    The label carries a post-marketing warning for deep vein thrombosis and pulmonary embolism, and TRAVERSE put a number on it: venous thromboembolism in 1.7% of men on testosterone against 1.2% on placebo over a mean 33 months of follow-up.

    Symptoms the label tells patients to report
    Leg pain, swelling and warmth, or sudden shortness of breath. The monitoring schedule is in the TRT guide.

    Heart, Blood Pressure and TRAVERSE

    The 2025 labels replaced the old "inconclusive" cardiovascular language with trial data.

    TRAVERSE trial, 5,198 men, mean 33 months: testosterone vs placebo (%)7.0%7.3%Major cardiac events1.7%1.2%Venous thromboembolism0.9%0.5%Pulmonary embolism02468Testosterone gelPlaceboFigures from the 2025 Azmiro and Xyosted labels

    TRAVERSE, the cardiovascular outcomes trial (testosterone gel vs placebo)

    Measure
    Result

    Population

    5,198 hypogonadal men aged 45 to 80 with cardiovascular disease or high risk

    Duration

    Mean 22 months on treatment, 33 months follow-up

    Major adverse cardiac events

    7.0% testosterone vs 7.3% placebo; non-inferiority met

    Went the other way

    More atrial fibrillation, acute kidney injury, pulmonary embolism; more fractures in a separate analysis

    The labels also carry the blood-pressure warning added in 2021. In the Xyosted ambulatory monitoring study, testosterone raised blood pressure by an average 3.9/1.5 mm Hg after 12 weeks, and the products are not recommended in men with uncontrolled hypertension. A blood-pressure check at each visit is the practical consequence.


    Estrogen, Gynecomastia and Water

    A fraction of injected testosterone is converted to estradiol by aromatase, more so in men with more body fat and more so at the peaks of a two-week schedule.

    What users describe in the days after a large injection:

    1. 1Puffiness and water retention
    2. 2Nipple sensitivity
    3. 3Mood swings

    The label lists gynecomastia and sodium and water retention. The Endocrine Society does not recommend routine aromatase inhibitors on TRT; most clinics manage estrogen first by splitting the dose into smaller, more frequent injections, which lowers the peak. Anastrozole on top of TRT lowers estradiol but also the bone-protective effect of estrogen, which is why it is reserved for symptomatic gynecomastia rather than a number on a lab report.


    Fertility and Testicular Size

    Exogenous testosterone shuts down LH and FSH, the pituitary hormones that drive sperm production and keep the testes at size. The label warns of oligospermia and, in the Azmiro version, azoospermia.

    In the early contraceptive trials of weekly 200 mg testosterone enanthate, most men reached azoospermia or severe oligospermia within months; recovery after stopping took a median of several months and was not universal.

    Men who may want children are advised in the guideline not to start, or to discuss hCG or clomiphene-based alternatives with a reproductive endocrinologist before the first injection.

    Skin, Hair and Mood

    Acne and oily skin come from the androgenic effect on sebaceous glands and are most noticeable in the first months and at higher doses.

    Male pattern hair loss is listed in the label and is driven by dihydrotestosterone in men with the genetic predisposition; the drug does not create the pattern, it accelerates it.

    Mood effects in the label run in both directions:

    1. 1At replacement doses: increased libido and energy, or anxiety and depression; the usual complaint is the swing that tracks a two-week cycle, which disappears with weekly dosing
    2. 2At supratherapeutic doses (abuse section): mania, paranoia, hostility, aggression, and withdrawal symptoms lasting weeks or months after stopping

    Injection-Site Problems

    Pain, redness and a firm lump for a few days are the normal course of 1 mL of oil in a muscle; the Azmiro study's 26% erythema rate shows how common mild reactions are.

    When it is more than that:

    1. 1Persistent heat, spreading redness, fever or drainage: an abscess, needs a clinician
    2. 2Coughing, chest tightness and dizziness in the minutes after injecting: a small amount of oil in a vein, the reason the label insists on intramuscular use and clinics teach careful technique

    Subcutaneous injection, used off-label, trades the muscle lump for a small bruise. The technique is in the injection guide.

    Frequently Asked Questions

    Injection-site pain or redness (26% mild erythema in the Azmiro study), acne and oily skin, fluid retention, mood and libido changes, and a rising hematocrit on blood tests.

    TRAVERSE found no excess of heart attack, stroke or cardiovascular death with testosterone versus placebo over about 33 months (7.0% vs 7.3%), but more venous clots, atrial fibrillation and fractures. The labels still warn that long-term injectable data are limited.

    Testosterone raises red-cell mass; a hematocrit above 54% is the Endocrine Society's threshold to stop, because thicker blood raises clot risk.

    It can, through conversion to estradiol; the label lists it. Smaller, more frequent doses lower the estrogen peak; aromatase inhibitors are reserved for symptomatic cases.

    It suppresses sperm production, often to zero, while in use. Recovery after stopping takes months and is not guaranteed; men planning children are advised not to start.

    Yes; the labels carry a blood-pressure warning, with an average rise of 3.9/1.5 mm Hg at 12 weeks in the Xyosted monitoring study, and advise against use with uncontrolled hypertension.

    Cypionat.com is an independent educational resource. We are not affiliated with Pfizer, Azurity or any manufacturer, pharmacy or clinic. This content is for informational purposes only and does not constitute medical advice. Images on this site are illustrative artwork made for editorial purposes; they do not show real products, packaging or labels and are not an advertisement or an offer to sell.

    Advertising